Publication:
Radiotherapy in patients with trachea tumours: A retrospective study and literature review

dc.contributor.authorSarihan, Süreyya
dc.contributor.authorBayram, Ahmet Sami
dc.contributor.authorMelek, Hüseyin
dc.contributor.authorGebitekin, Cengiz
dc.contributor.buuauthorSARIHAN, SÜREYYA
dc.contributor.buuauthorBAYRAM, AHMET SAMİ
dc.contributor.buuauthorMELEK, HÜSEYİN
dc.contributor.buuauthorGEBİTEKİN, CENGİZ
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentGöğüs Cerrahisi Ana Bilim Dalı
dc.contributor.orcid0000-0003-4816-5798
dc.contributor.orcid0000-0003-0684-0900
dc.contributor.researcheridAAE-1069-2022
dc.contributor.researcheridAAI-5039-2021
dc.contributor.researcheridJCE-0097-2023
dc.contributor.researcheridABB-7580-2020
dc.contributor.researcheridAAH-4970-2021
dc.date.accessioned2024-07-09T10:27:26Z
dc.date.available2024-07-09T10:27:26Z
dc.date.issued2020-01-01
dc.description.abstractOBJECTIVEIn this study, we aimed to evaluate our patients with tracheal tumours treated with primary or adjuvant radiotherapy (RT) and to review the current literature on the subject.METHODSBetween 1998 and 2017, eight patients underwent RT. Their median age was 37 years (15-53). The diagnosis was adenoid cystic carcinoma in five patients, squamous cell carcinoma in three patients and mucoepidermoid carcinoma in one patient. Resection type was R0 (1), R1 (4), R2 (1), and biopsy (2). The median tumour size was 2.6 cm (2-5). Median 59.4 Gy RT (32.4-66.6) was given, and weekly cisplatin was administered to four patients concomitantly.RESULTSWith a median follow-up of 85 months (4-189), five patients were alive. The 5-year overall and disease-free survival rates were 83% and 67%, respectively. There was no local recurrence in any patient. In one patient who had a complete response with curative chemo-RT, dilatation was performed five times in 10 years because tracheal stenosis developed at 60 months.CONCLUSIONTrachea tumours are rare, and the primary treatment is surgery. Adjuvant RT is controversial in R0 cases. In unresectable cases, RT is the primary treatment modality. We believe that our treatment results will contribute to the literature on the subject.
dc.identifier.doi10.5505/tjo.2019.2072
dc.identifier.endpage177
dc.identifier.issn1300-7467
dc.identifier.issue2
dc.identifier.startpage167
dc.identifier.urihttps://doi.org/10.5505/tjo.2019.2072
dc.identifier.urihttps://onkder.org/pdf/pdf_TOD_1128.pdf
dc.identifier.urihttps://hdl.handle.net/11452/43078
dc.identifier.volume35
dc.identifier.wos000537954700008
dc.indexed.wosWOS.ESCI
dc.language.isoen
dc.publisherKare Yayınevi
dc.relation.journalTürk Onkoloji Dergisi-Turkish Journal of Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAdenoid cystic carcinoma
dc.subjectSquamous-cell-carcinoma
dc.subjectRadiation-therapy
dc.subjectMalignant neoplasms
dc.subjectSurvival outcomes
dc.subjectCancer
dc.subjectPrognosis
dc.subjectLocal control
dc.subjectRadiotherapy
dc.subjectSurvival
dc.subjectTrachea tumor
dc.subjectOncology
dc.titleRadiotherapy in patients with trachea tumours: A retrospective study and literature review
dc.typeReview
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Radyasyon Onkolojisi Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Göğüs Cerrahisi Ana Bilim Dalı
relation.isAuthorOfPublication07b16629-e65c-40b0-b11d-825ad7943570
relation.isAuthorOfPublicationbdb7801d-f0bc-4abc-af2c-5bf7df23fbd5
relation.isAuthorOfPublicationa600fc7e-754b-4a62-957d-5139e02d21ca
relation.isAuthorOfPublication029ec57f-2451-4282-8110-61c87cd6a41d
relation.isAuthorOfPublication.latestForDiscovery07b16629-e65c-40b0-b11d-825ad7943570

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Sarihan_vd_2020.pdf
Size:
390.46 KB
Format:
Adobe Portable Document Format

Collections